A PHASE 1 TRIAL OF THE MENIN INHIBITOR ZIFTOMENIB IN COMBINATION WITH CHEMOTHERAPY FOR CHILDREN WITH RELAPSED/REFRACTORY KMT2A-REARRANGED, NUP98-REARRANGED, OR NPM1-MUTANT ACUTE LEUKEMIA

Registry ID

APAL2020K

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

PEDAL BLOOD CANCER UNITED, LLC

Start date

2025-03-05

Last update

2024-09-11

Conditions

• LEUKEMIA

Related clinical trials

• A PHASE 2 STUDY OF REVUMENIB (SNDX-5613) IN COMBINATION WITH CHEMOTHERAPY FOR PATIENTS WITH RELAPSED OR REFRACTORY KMT2A-REARRANGED INFANT LEUKEMIA
• A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ADMINISTRATION OF SUBCUTANEOUS BLINATUMOMAB FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B ALL
• AN EXTENSION STUDY OF VENETOCLAX FOR SUBJECTS WHO HAVE COMPLETED A PRIOR VENETOCLAX CLINICAL TRIAL
• IDENTIFICATION AND EVALUATION OF PATIENTS AT RISK OF DEVELOPING CARDIOTOXICITY AFTER RECEIVING CHEMOTHERAPY FOR BREAST CANCER, LEUKEMIA OR LYMPHOMA
• A PHASE 3 RQANDOMIZE TRIAL OF INOTUZUMAB OZOGAMICIN (IND#: 133494, NSC#: 772518) FOR NEWLY DIAGNOSED HIGH-RISK B-ALL; RISK-ADAPTED POST-INDUCTION THERAPY FOR HIGH-RISK B-ALL, MIXED PHENOTYPE ACUTE LEUKEMIA, AND DISSEMINATED B-LLY
• LAROTRECTINIB (LOXO-101, NSC# 788607, IND# 141824) FOR PREVIOUSLY UNTREATED TRK FUSION PEDIATRIC SOLID TUMORS AND TRK FUSION RELAPSED PEDIATRIC ACUTE LEUKEMIAS

View on source registry